RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

RadNet CFO Mark Stolper will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 7:45 a.m. ET. The announcement provides an investor-engagement update but contains no financial results, guidance, or operational developments.

Analysis

This is not an earnings, contract, reimbursement, or capital-allocation event; the standalone signal does not support a directional position in RDNT. The practical value is informational: management's conference messaging can shape near-term expectations around imaging-volume growth, reimbursement rates, de novo center ramp costs, artificial-intelligence adoption, and leverage reduction—variables that determine whether RDNT retains a premium growth-services multiple.

For the next 1-3 months, the relevant setup is expectation risk rather than an identifiable catalyst. A constructive update on same-center volumes and operating leverage could tighten estimates ahead of the next earnings release, while any incremental commentary on payer pressure, labor costs, or delayed imaging-center openings would be more consequential than the presentation itself. MS has no investable read-through from its role as conference host.

The contrarian point is that investor conferences often generate algorithmic or retail attention without changing fundamentals. Unless management provides quantifiable guidance that differs from prior disclosures, any post-presentation move should fade; use unusual strength or weakness to assess positioning rather than to chase price action. The thesis becomes actionable only if commentary alters the market's view of EBITDA growth, free-cash-flow conversion, or net leverage trajectory over the next 6-18 months.

Key Decisions for Investors

• No new directional RDNT position solely on the September 16 presentation; treat it as a monitoring event, not a catalyst.
• Set an alert for explicit changes to same-center imaging volumes, reimbursement-rate outlook, or adjusted EBITDA guidance. A guidance raise with evidence of margin conversion would support a 1-3 month long RDNT tactical trade; absent revised estimates, avoid chasing a conference-day rally.
• For an existing RDNT long, review the webcast for commentary on debt paydown and de novo-center ramp timing. Reduce exposure if management signals slower free-cash-flow conversion or incremental leverage, as these would challenge the 6-18 month multiple-support thesis.
• If RDNT moves materially on elevated volume without new quantified information, consider waiting for the next earnings release rather than adding; falsification of a bullish setup would be lower volume growth or margin guidance sufficient to drive consensus EBITDA estimates down.